The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

Does salpingectomy prevent ovarian cancer? Let’s prove it.

The SOROCk clinical trial, NRG CC008 (NCT04251052)

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Abstract

The majority of epithelial ovarian cancer is diagnosed at an advanced stage and long-term survival is low. Since ovarian cancer screening is ineffective, the main focus to reduce ovarian cancer mortality is prevention. 

For individuals at increased risk of ovarian carcinoma, risk-reducing bilateral salpingo-oophorectomy (RRSO) is highly effective, but uptake at the recommended age is suboptimal, likely due to concerns about premature menopause. 

Mounting evidence suggests that many “ovarian” cancers originate in the fallopian tube, making bilateral salpingectomy with delayed oophorectomy an attractive, but as of yet, unproven option for risk-reduction in those who decline RRSO. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.
Clinical Roundup

Perioperative Imfinzi + neoadjuvant EV improved EFS and OS in muscle-invasive bladder cancer, phase III VOLGA trial shows

High-level results from a planned interim analysis of the VOLGA phase III trial showed perioperative treatment with Imfinzi (durvalumab) in combination with neoadjuvant enfortumab vedotin demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival in patients with muscle-invasive bladder cancer versus standard of care. 
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account